Biochem/physiol Actions
CSRM617 is an ONECUT2 (OC2) inhibitor that directly targets OC2 HOX domain (KD = 7.43 μM) and disrupts OC2 target genes promoter binding. CSRM617 blocks OC2-dependent prostate cancer growth in cultures (IC50 = 4-50 μM; 48 h) via apoptosis induction (fold of untreated annexin V population = 2.3/10 μM, 3.5/20 μM; 22Rv1) and exhibits in vivo efficacy against metastases as well as the growth of established 22Rv1 tumor in mice in vivo (50 mg/kg/day ip.).
- UPC:
- 12352200
- Condition:
- New
- Availability:
- 3-5 Days
- Weight:
- 1.00 Ounces
- HazmatClass:
- No
- MPN:
- SML2608-25MG
- CAS:
- 1353749-74-2